Phase II Study Of First-line SBRT In Patients With Non-Metastatic Unresectable Pancreatic Cancer

Study Overview

Phase II Study of First-line SBRT in Patients With Non-Metastatic Unresectable Pancreatic Cancer

The purpose of this study is to see if SBRT will be a better way to treat pancreas cancer and to find out what effects, good and/or bad, this treatment will have on participants and their cancer.

The standard treatment for cancer of the pancreas is surgery (if possible), external beam radiation therapy and/or chemotherapy. These standard treatments are not a cure and often extend life by just a few months. Recently, a new approach has been developed, called stereotactic body radiation therapy (SBRT). Based on the results of earlier studies using SBRT, the study doctors at Moffitt feel this is a reasonable alternative to the standard treatment for your disease. Stereotactic body radiation therapy (SBRT) delivers high radiation doses to the tumor every day for 5 days which gives the usual 5-6 week course of radiation in less than a week. It has also been shown to have much less side effects. The purpose of this study is to see if SBRT will be a better way to treat pancreas cancer and to find out what effects, good and/or bad, this treatment will have on you and your cancer. Six patients will be asked to be part of a subgroup called TBRI (Tissue, Blood, Research Imaging). In this subgroup, the investigators want to study if there is early death of tumor cells from the treatment by looking at the tumor using PET/CT scans and biopsies, and by testing your body's white blood cells taken by a procedure called leukapheresis. You do not have to take part in the TBRI subgroup to get treatment on this study with SBRT.

Pancreatic Tumor

RADIATION: Stereotactic Body Radiation Therapy (SBRT)
RADIATION: Tissue, Blood, Research Imaging (TBRI)

MCC-16459

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates	Results Reporting Dates	Study Record Updates
First Submitted 2011-09-13	Results First Submitted N/A	Last Update Submitted that met QC Criteria 2017-02-21
First Submitted that Met QC Criteria 2011-09-14	Results First Submitted that Met QC Criteria N/A	Last Update Posted (ACTUAL) 2017-02-23
First Posted (ACTUAL) 2011-09-15	Results First Posted N/A	Last Verified 2017-02

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
Treatment

Allocation:
Non Randomized

Interventional Model:
Parallel

Masking:
None

Arms and Interventions

Participant Group/Arm	Intervention/Treatment
ACTIVE_COMPARATOR: TBRI Subgroup: TBRI and SBRT Six patients will be asked to be part of a subgroup called TBRI (Tissue, Blood, Research Imaging). In this subgroup, we want to study if there is early death of tumor cells from the treatment by looking at the tumor using PET/CT scans and biopsies, and by	RADIATION: Stereotactic Body Radiation Therapy (SBRT) Everyone who takes part in this study will receive SBRT. After making an individual radiation plan for each participant, they will receive 5 days of radiation to the pancreas. Participants will have follow-up visits with blood tests one month after the en RADIATION: Tissue, Blood, Research Imaging (TBRI) Post-SBRT procedures (day 1, 3, 5 of SBRT, and 4 weeks after) A) Endoscopic or CT guided biopsy of treated pancreatic cancer to assess 1. Necrosis/apoptosis 2. Lymphocyte infiltrate and antigen presenting cells B) Imaging to evaluate cell death (day 1, 3
ACTIVE_COMPARATOR: SBRT Alone 1. 30 Gy in 5 fractions to pancreatic tumor 2. 50 Gy in 5 daily consecutive fractions unresectable portion and avoiding bowel, stomach, and duodenum	RADIATION: Stereotactic Body Radiation Therapy (SBRT) Everyone who takes part in this study will receive SBRT. After making an individual radiation plan for each participant, they will receive 5 days of radiation to the pancreas. Participants will have follow-up visits with blood tests one month after the en

Participant Group/Arm

Intervention/Treatment

ACTIVE_COMPARATOR: TBRI Subgroup: TBRI and SBRT

Six patients will be asked to be part of a subgroup called TBRI (Tissue, Blood, Research Imaging). In this subgroup, we want to study if there is early death of tumor cells from the treatment by looking at the tumor using PET/CT scans and biopsies, and by

RADIATION: Stereotactic Body Radiation Therapy (SBRT)

Everyone who takes part in this study will receive SBRT. After making an individual radiation plan for each participant, they will receive 5 days of radiation to the pancreas. Participants will have follow-up visits with blood tests one month after the en

RADIATION: Tissue, Blood, Research Imaging (TBRI)

Post-SBRT procedures (day 1, 3, 5 of SBRT, and 4 weeks after) A) Endoscopic or CT guided biopsy of treated pancreatic cancer to assess 1. Necrosis/apoptosis 2. Lymphocyte infiltrate and antigen presenting cells B) Imaging to evaluate cell death (day 1, 3

ACTIVE_COMPARATOR: SBRT Alone

1. 30 Gy in 5 fractions to pancreatic tumor 2. 50 Gy in 5 daily consecutive fractions unresectable portion and avoiding bowel, stomach, and duodenum

RADIATION: Stereotactic Body Radiation Therapy (SBRT)

Everyone who takes part in this study will receive SBRT. After making an individual radiation plan for each participant, they will receive 5 days of radiation to the pancreas. Participants will have follow-up visits with blood tests one month after the en

Primary Outcome Measures	Measure Description	Time Frame
Number of Participants With Overall Survival (OS)	Patients will be followed for 36 months to determine overall survival even after completion of the experimental portion of the protocol. Patients will be followed every 3 months. All patients will be referred for chemotherapy at the completion of radiation.	36 Months

Secondary Outcome Measures	Measure Description	Time Frame
Number of Participants With Reduction in Size of Primary Tumor	Patients will undergo 64 slice helical computed tomography (CT) scan and feeding (FDG) pressure equalizing tube (PET)-CT scan pretreatment and at the conclusion of the study which will be separated by a 5 week time span. Subsequent helical CT and FDG PET-CT scans will be performed at 3, 6, 9 and 12 months with CA 19-9 levels. The Response Evaluation Criteria In Solid Tumors (RECIST) criteria will be used to measure clinical response. Time to local and distant disease progression will also be measured.	12 Months
Number of Participants With Adverse Events (AEs)	Toxicity response will be assessed and reported using the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.	36 Months

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
18 Years

Accepts Healthy Volunteers:

Biopsy proven, non-metastatic, pancreatic cancer
Unresectable disease based on institutional standardized criteria for unresectability
Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2
CT scan of chest and abdomen (3-phase pancreas protocol), and PET-CT within 4 weeks of study entry
Patients with biliary or gastroduodenal obstruction must have drainage, duodenal stenting, or gastric bypass prior to initiating radiation
All disease must be encompassed in a single radiation field
No evidence or history of an autoimmune dysfunction
Negative pregnancy test within 7 days of study entry
No prior or concurrent chemotherapy
No previous or concurrent immunotherapy for pancreatic cancer
Liver enzymes ≤ 3 times upper limit of normal (ULN): total bilirubin (Tbili) ≤ 3.9 (biliary stents are allowed); aspartic transaminase (AST) ≤ 177; alanine transaminase (ALT) ≤ 198; Alkaline phosphatase (ALK-P) ≤ 378
Adequate pretreatment organ function: Creatinine no greater than 1.5mg/dL; Total calcium no greater than 11.0mg/dL; prothrombin time (PT) no greater then 14 seconds; partial thromboplastin time (PTT) no greater then 40 seconds
Ability to give informed consent
Adequate baseline hematopoietic function: total white blood cell count equal to or greater than 3,000/mm³; absolute granulocyte count greater than 1,500/mm³; absolute lymphocyte count greater than 500/mm³; platelet count equal to or greater than 100,000/mm³

All Participant inclusion criteria
Amenable to leukapheresis as determined by a leukapheresis nurse
Primary tumor that is accessible to direct intratumoral injection by CT-guidance confirmed by interventional radiologist
No history of autoimmune disease
No history of human immunodeficiency virus (HIV) or acquired immune deficiency syndrome (AIDS) or other immunosuppressive diseases
No active viral or bacterial infection
No use of steroids or any other immunosuppressive drug at least 4 weeks prior to enrollment on study

Prior history of radiotherapy that overlaps with the planned ports to the primary pancreatic tumor
Patients with tumors that are not accessible to direct access cannot be included in the study.
Prior or concurrent chemotherapy
Prior history of antineoplastic therapy or irradiation
Prior treatment with anti-tumor vaccines not allowed
Patients with a history of autoimmune diseases
A history of HIV infection, AIDS or other immunosuppressive disease state. The need to exclude patients with HIV/AIDS is because one of the endpoints of the study is immune response. People with HIV have a compromised immune system and enrollment in this study could confound the results (TBRI only)
Patients requiring corticosteroids are ineligible because one of the endpoints of the study is immune response. Since steroids modulate the immune system, enrollment of patients on steroids could confound the results. There must be no use of corticosteroids in the fours weeks preceding entry into the study (TBRI only).
Active bacterial, fungal or viral infection
Active bleeding (hemoptysis, melena, etc.)
Women who are currently pregnant or actively breast feeding. Women of childbearing potential must have a negative serum pregnancy test and must use effective contraception during trial participation
Any medical or psychiatric illness which in the opinion of the principal investigator might compromise a patient's ability to tolerate or complete treatment
Any patient requiring blood thinners (due to risk of gastrointestinal [GI] bleed)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

PRINCIPAL_INVESTIGATOR: Ravi Shridhar, M.D., Ph.D., H. Lee Moffitt Cancer Center and Research Institute

Publications

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

No publications available

Learn

Resources

PatientS

Caregivers

Clinical Trial Record